1. Strength and stability testing for compounded preparations;Allen;USP Compound. Expert Committee,2014
2. Comparative pharmacokinetics of commercially available cannabidiol isolate, broad-Spectrum, and full-Spectrum products;Berthold;Eur. J Drug Metab. Pharmacokinet,2023
3. Food and Drug Administration (2018). FDA approves first drug comprised of an active ingredient derived from Marijuana to treat rare, severe forms of epilepsy. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms (Accessed 29 May 2023).
4. Food and Drug Administration (2019). FDA is committed to sound, science-based policy on CBD. https://www.fda.gov/news-events/fda-voices/fda-committed-sound-science-based-policy-cbd (Accessed 27 May 2023).
5. Food and Drug Administration (2020a). FDA concludes that existing regulatory frameworks for foods and supplements are not appropriate for cannabidiol, will work with congress on a new way forward. https://www.fda.gov/news-events/press-announcements/fda-concludes-existing-regulatory-frameworks-foods-and-supplements-are-not-appropriate-cannabidiol (Accessed 8 November 2023).